DexCom, Inc.
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG000QTF8K1
DXCM
DexCom, Inc.
GICS: -
·
Sector: Healthcare
·
Sub-Sector: Medical Devices
NAME
DexCom, Inc.
ISIN
US2521311074
TICKER
DXCM
MIC
XNAS
REUTERS
DXCM.OQ
BLOOMBERG
DXCM US
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Thu, 24.10.2024
DexCom
US2521311074
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2024.
Third Quarter 2024 Financial Highlights:
Revenue grew 2% year-over-year to $994.2 million on a reported basis and 3% year-over-year on an organic1 basis.
U.S. revenue declined 2% and international revenue grew 12% on a reported...
Mon, 21.10.2024
DexCom
US2521311074
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ:DXCM) and reminds investors of the October 21, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faru...
Fri, 18.10.2024
DexCom
US2521311074
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024. DexCom describes itself as an “international company that develops, manufactures, and distributes continuous glucose monitoring syst...
Thu, 17.10.2024
DexCom
US2521311074
The Law Offices of Frank R. Cruz reminds investors of the upcoming October 21, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) securities between January 8, 2024 to July 25, 2024, inclusive (the “Class Period”).
If you are a shareho...
Tue, 15.10.2024
DexCom
US2521311074
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between April 28, 2023 and July 25, 2024, inclusive (the “Class Period”) The lead p...
Wed, 09.10.2024
DexCom
US2521311074
Labaton Keller Sucharow LLP (“Labaton”) announces that, on October 8, 2024, it filed a securities class action lawsuit (the “Complaint”) on behalf of its clients Oakland County Employees’ Retirement System and Oakland County Voluntary Employees’ Beneficiary Association (the “Oakland County Funds”) against DexCom, Inc. (“DexCom” or the “Company”) (...
Tue, 24.09.2024
DexCom
US2521311074
Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024 (the “Class Period”).
CLICK HERE TO JOIN THE CASE
If you are an investor in DexCom and have suffered losses, you may CLICK HERE to contact us. Yo...
Mon, 23.09.2024
DexCom
US2521311074
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, in partnership with the nonprofit Beyond Type 2, are teaming up with author, producer and actress Retta to establish National Glucose Awareness Week from Sept. 23-29, 2024. National Glucose Awareness Week will help close the glucose k...
Wed, 18.09.2024
DexCom
US2521311074
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company’s groundbreaking NIL (name, image, likeness) program exclusively for college athletes with diabetes.
This press release features multimedia. View the full ...
Wed, 18.09.2024
DexCom
US2521311074
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of those who acquired Dexcom Inc. (“Dexcom” or the “Company”) (NASDAQ: DXCM) securities during the period of January 8, 2024 to July 25, 2024, inclusive (“the Class Period”). ...
Information on product placements
